Page 181 - IJB-10-6

International Journal of Bioprinting 3D bioprinting technology for brain tumor

145. Lee SH, Kang MS, Jeon S, et al. 3D bioprinting of human 155. Ryu KY, Lee HJ, Woo H, et al. Dasatinib regulates LPS-
mesenchymal stem cells-laden hydrogels incorporating induced microglial and astrocytic neuroinflammatory
MXene for spontaneous osteodifferentiation. Heliyon. responses by inhibiting AKT/STAT3 signaling. J
2023;9(3):e14490. Neuroinflammation. 2019;16(1):190.
doi: 10.1016/j.heliyon.2023.e14490 doi: 10.1186/s12974-019-1561-x
146. Vignesh A, Binoy A, Thurakkal L, Bhuvanesh NS, 156. Liu PC, Lu G, Deng Y, et al. Inhibition of NF-kappaB
Sadhukhan S, Porel M. Pyrene aroylhydrazone-based Pd (II) pathway and modulation of MAPK signaling pathways in
complexes for DNA/protein binding, cellular imaging and glioblastoma and implications for lovastatin and tumor
in vitro anticancer activity via ROS production. J Mol Struct. necrosis factor-related apoptosis inducing ligand (TRAIL)
2024;1295:136693. combination therapy. PLoS One. 2017;12(1):e0171157.
doi: 10.1016/j.molstruc.2023.136693 doi: 10.1371/journal.pone.0171157
147. Ma Q, Sun J, Wang H, et al. Far upstream element-binding 157. Zhu Z, Zhang P, Li N, et al. Lovastatin enhances cytotoxicity
protein 1 confers lobaplatin resistance by transcriptionally of temozolomide via impairing autophagic flux in
activating PTGES and facilitating the arachidonic acid glioblastoma cells. Biomed Res Int. 2019;2019:2710693.
metabolic pathway in osteosarcoma. Med Comm (2020). doi: 10.1155/2019/2710693
2023;4(3):e257. 158. Wu Q, Zhu C, Zhang S, Zhou Y, Zhong Y. Hematological
doi: 10.1002/mco2.257
toxicities of concurrent chemoradiotherapies in head and
148. Du L, Fei Z, Song S, Wei N. Antitumor activity of Lobaplatin neck cancers: comparison among cisplatin, nedaplatin,
against esophageal squamous cell carcinoma through lobaplatin, and nimotuzumab. Front Oncol. 2021;11:762366.
caspase-dependent apoptosis and increasing the Bax/Bcl-2 doi: 10.3389/fonc.2021.762366
ratio. Biomed Pharmacother. 2017;95:447-452.
doi: 10.1016/j.biopha.2017.08.119 159. Hua S, Kong X, Chen B, et al. Anticancer mechanism
149. Vaz-Salgado MA, Villamayor M, Albarran V, et al. Recurrent of lobaplatin as monotherapy and in combination with
glioblastoma: a review of the treatment options. Cancers paclitaxel in human gastric cancer. Curr Mol Pharmacol.
(Basel). 2023;15(17):4279. 2018;11(4):316-325.
doi: 10.3390/cancers15174279 doi: 10.2174/1874467211666180813095050
160. Weller M, Le Rhun E. How did lomustine become standard
150. Yamamuro S, Takahashi M, Satomi K, et al. Lomustine
and nimustine exert efficient antitumor effects against of care in recurrent glioblastoma? Cancer Treat Rev.
glioblastoma models with acquired temozolomide 2020;87:102029.
resistance. Cancer Sci. 2021;112(11):4736-4747. doi: 10.1016/j.ctrv.2020.102029
doi: 10.1111/cas.15141 161. Mekala JR, Adusumilli K, Chamarthy S, Angirekula HSR.
Novel sights on therapeutic, prognostic, and diagnostics
151. Schneider M, Potthoff AL, Evert BO, et al. Inhibition of
Intercellular Cytosolic Traffic via Gap Junctions Reinforces aspects of non-coding RNAs in glioblastoma multiforme.
Lomustine-Induced Toxicity in Glioblastoma Independent Metabolic Brain Dis. 2023;38(6):1801-1829.
of MGMT Promoter Methylation Status. Pharmaceuticals doi: 10.1007/s11011-023-01234-2
(Basel). 2021;14(3):195. 162. Wang X, Luo Y, Ma Y, Wang P, Yao R. Converging
doi: 10.3390/ph14030195 bioprinting and organoids to better recapitulate the tumor
microenvironment. Trends Biotechnol. 2024;42(5):648-663.
152. Amrein PC. Low-dose dasatinib: when less can be more.
Lancet Haematol. 2021;8(12):e867-e868. doi: 10.1016/j.tibtech.2023.11.006
doi: 10.1016/S2352-3026(21)00342-2 163. Li Y, Liu J, Xu S, Wang J. 3D bioprinting: an important tool
for tumor microenvironment research. Int J Nanomed.
153. Owusu A, Bonnaire K, Hailemeskel B. Lovastatin use in
transplant: a review and survey. Int J Pharm Res Allied Sci. 2023:18;8039-8057.
2024;13(1):83-90. doi: 10.2147/IJN.S435845
doi: 10.51847/LJ2kXhjbtG 164. Shah B, Dong X. Current status of in vitro models of the
blood-brain barrier. Curr Drug Deliv. 2022;
154. Alhalabi OT, Fletcher MNC, Hielscher T, et al. A novel patient
stratification strategy to enhance the therapeutic efficacy doi: 10.2174/1567201819666220303102614
of dasatinib in glioblastoma. Neuro Oncol. 2022;24(1): 165. Yigci D, Sarabi MR, Ustun M, et al. 3D bioprinted glioma
39-51. models. Prog Biomed Eng. 2022;4(4):042001.
doi: 10.1093/neuonc/noab158 doi: 10.1088/2516-1091/ac7833

Volume 10 Issue 6 (2024) 173 doi: 10.36922/ijb.4166